Shanghai Medicilon Inc.

  On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list. Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected!  This is the Science and Technology Commission of Shanghai Municipality's high recognition of Medicilon's technological innovation and R&D capabilities, and is also a spur and incentive for Medicilon to continuously improve its service levels. The Shanghai professional technical service platform is an important part of Shanghai's scientific and technological innovation service system. It is a scientific research entity built on the basis of enterprises, scientific research institutes, universities or other institutions with scientific and technological innovation capabilities.  It

  Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene.  The strong support provided in collaboration projects has been recognized by client again. Medicilon and SicaGene: Go Deep Alone, Go Far Together The collaboration stems from a shared vision in the field of nucleic acid drugs.  Antisense oligonucleotide drugs can break through the "undruggable targets" limitations of traditional small molecule drugs, but they also have extremely high technical barriers and development difficulties.  As one of the first China innovative pharmaceutical companies to enter the ASO field, SicaGene has independently developed and constructed core technology platforms such as  SicaScreenTM、SicaChemistryTM、SicaDeliveryTM , focusing on drug development in the fields of cardiovascular disease, viruses, and ophthalmology.  SicaGene has also achieved efficient development of ASO drugs with high activity, low dosage, long administration cycle, good clini

The field of metabolomics, particularly the identification and quantification of metabolites, has been greatly expedited by advancements in liquid chromatography-mass spectrometry (LC-MS) technology. LC-MS combines the physical separation properties of liquid chromatography with the mass analysis capabilities of mass spectrometry, thus rendering an unparalleled potential for accurate profiling of metabolites in biological samples. The power of metabolomics lies in its ability to survey the complete set of metabolites or the metabolome in biological systems. However, the extensive diversity of the metabolome, characterized by wide-ranging physicochemical properties, presents a formidable challenge for any single analytical methodology. That’s where LC-MS comes into play. In LC-MS, liquid chromatography separates complex biological samples into individual metabolite components, while mass spectrometry provides exact mass measurements facilitating the identification and quantification

Active metabolomics is swiftly becoming a revolutionary tool in the realm of scientific research, providing us an in-depth perspective to the world of active metabolites in biological systems. Through its multi-disciplinary approach, active metabolomics, with a foundation in biochemistry, molecular biology, and computational biology, offers insights into the intricate networks of metabolites at play within biological organisms. Active metabolites form the functional backbone within biological systems. They range from basic building blocks such as glucose and amino acids to signaling molecules such as hormones, neurotransmitters, and other biologically active entities. The identification and understanding of these metabolites are paramount for a comprehensive understanding of physiological functions in living organisms and unraveling complex biological processes. Active metabolomics provides us with a breakthrough, allowing a systematic approach to studying active metabolites within

Active metabolomics is a scientific method to study the activity of metabolites in organisms. It analyzes the changes in metabolites in organisms to understand the metabolic state of organisms under specific physiological or pathological conditions. The use of active metabolomics to identify bioactive metabolites can help us deeply understand the metabolic process of organisms, discover new drug targets, and study the occurrence and development mechanisms of diseases. The following are general steps for identifying bioactive metabolites using active metabolomics: 1. Sample collection: Collect biological samples in different physiological or pathological states, such as cells, tissues, blood, urine, etc. 2. Metabolite extraction: Extract metabolites from the sample. Commonly used methods include solvent extraction, solid phase extraction, etc. 3. Metabolite analysis: Use chromatography-mass spectrometry and other techniques to analyze the extracted metabolites to obtain information such

Active metabolomics has become a powerful and disruptive research tool, taking our understanding of bioactive metabolites to a whole new level. This brand-new research method uses high-throughput and high-sensitivity analysis technology to conduct comprehensive qualitative and quantitative measurements of all metabolites in biological systems and analyze their interrelationships to gain a deeper understanding of biological systems. Bioactive metabolites, including various enzymes, hormones, etc., are indispensable components in life activities. However, precise identification of these metabolites is not easy in the face of complex biological systems. Traditional biochemical techniques often can only study a specific metabolite due to time and cost considerations. On the contrary, active metabolomics breaks this limitation and provides a global perspective, allowing us to observe and analyze all active metabolites in organisms. Act

  Liquid Chromatography-Mass Spectrometry (LC-MS) is a signature technology in metabolomics used for the precise identification and quantification of metabolites. Metabolomics, the comprehensive analysis of metabolites in a biological system, contributes to the understanding of an organism’s physiology and pathology. Indeed, LC-MS as a method in metabolomics holds the power to fuel discoveries in manifold scientific domains. The journey of studying metabolites using LC-MS begins with sample preparation where metabolites are extracted from their native biological matrices. The aim is to retain the structural integrity and relative concentration of the metabolites in the sample. The prepared sample advances to the liquid chromatography component of the system. The purpose of this stage is to separate the plethora of metabolites present in the sample based on characteristics like polarity, charge, and size. Considering the complexity

On January 8, 2024, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan Pharmaceutical) issued an announcement, saying that its holding subsidiary Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. has recently received the approval of the National Medical Products Administration (NMPA) to issue a "Drug Clinical Trial Approval Notice" for the new Class 1 chemical drug CSCJC3456 tablets. Shanghai Medicilon Inc. (Medicilon), as a partner of Changshan Pharmaceutical, has efficiently completed most of the preclinical research work of CSCJC3456, including drug efficacy, pharmacokinetics and safety evaluation promoting the project to quickly complete the preclinical research and development process. Accelerate Drug Innovation and Development      Medicilon’s One-Stop Shop to Assist Drug Preclinical Research and Development As a one-stop preclinical R&D service platform, Medicilon actively expands its development layout in popular areas

  On January 8, Dr. Xiaobao Yang, Chairman and CEO of Gluetacs Therapeutics (Gluetacs) awarded Shanghai Medicilon Inc. (Medicilon) the "2023 Best Partner Award”.  Dr. Jinna Cai, Chief Commercial Officer of Medicilon, and Bolin Zhang, Director of CMC of Key Account Development Department, attended the award ceremony. Medicilon and Gluetacs: Going in both directions, achieving each other’s achievements Dr. Xiaobao Yang, Chairman and CEO of Gluetacs, affirmed the efficient service capabilities of Medicilon’s one-stop biopharmaceutical preclinical R&D service platform at the award ceremony, “In the past two years, Gluetacs’  GT919  and GT929 have been clinically approved in China and the United States, which is inseparable from Medicilon’s strong support.  Even for difficult trials, the Medicilon team was able to deliver beyond expectations, which makes us feel reassured and confident in our future collaboration.” Dr. Jinna Cai, Chief Commercial Officer of Medicilon, said, “Thanks

With the continuous advancement of technology, Biomedicineis booming, and drug forms vary greatly, extending from traditional chemicals, antibodies, proteins, and peptides to cells, nucleic acids, and other forms.  The continuous emergence of new drug forms also poses some high requirements and new challenges to drug related bioanalytical technologies, and new analytical technologies are constantly being introduced.  Medicilon New Media’s bioanalysis series column continues to invite senior professionals in the field to talk and discuss about bioanalysis from different perspectives.  In this issue, we will share a different analysis technology for nucleic acid drugs: bDNA . In recent years, nucleic acid drugs have ushered in a stage of rapid development.  Since 2016, a total of 15 nucleic acid drugs have been successfully approved for marketing in the United States and/or the European Union, including 13 oligonucleotide drugs and 2 mRNA vaccines.  Among them, 8 of the oligonucleotide d